» Articles » PMID: 25812712

Factors Associated with Short-term Local Recurrence of Liver Cancer After Percutaneous Ablation Using Irreversible Electroporation: a Prospective Single-center Study

Overview
Date 2015 Mar 28
PMID 25812712
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the risk factors associated with short-term local recurrence of malignant liver lesions after irreversible electroporation (IRE).

Materials And Methods: Thirty-nine consecutive patients (79 malignant liver lesions) were treated with IRE, of whom 14 were excluded from the analysis (including 12 without 6 mo of follow-up and two with incomplete ablation). The remaining 25 patients (aged 59.4 y ± 11.2) had 48 malignant liver lesions, including 22 hepatocellular carcinomas (HCCs), six cholangiocellular carcinomas, and 20 metastatic liver cancers. Multivariate analyses were used to evaluate the associations of risk factors with early recurrence. The characteristics of patients, lesions, and IRE procedures were assessed by logistic regression.

Results: Fourteen of the 48 treated lesions (29.2%) showed early local recurrence after 6 months. Tumor volume (< 5 cm(3) vs ≥ 5 cm(3); P = .022) and underlying disease type (HCC, cholangiocellular carcinoma, or metastatic disease; P = .023) were independently associated with early local recurrence. However, distances to the surrounding portal veins (< 0.5 cm vs ≥ 0.5 cm; P = .810), hepatic veins (P = .170), hepatic arteries (P = .761), and bile ducts (P = .226) were not significantly associated with local recurrence.

Conclusions: Because short distances to the surrounding vessels were not associated with early local recurrence, percutaneous IRE might provide an alternative treatment option for perivascular tumors. However, patients with larger tumor volumes appeared to be poor candidates for percutaneous IRE. Regarding the different types of treated lesions, patients with HCC had significantly better outcomes.

Citing Articles

Clinical translation of abdominal histotripsy: a review of preclinical studies in large animal models.

Falk K, Laeseke P, Kisting M, Zlevor A, Knott E, Smolock A Int J Hyperthermia. 2023; 40(1):2272065.

PMID: 37875279 PMC: 10629829. DOI: 10.1080/02656736.2023.2272065.


Ablative Therapy in Non-HCC Liver Malignancy.

Robinson T, Pebror T, Krosin M, Koniaris L Cancers (Basel). 2023; 15(4).

PMID: 36831543 PMC: 9954041. DOI: 10.3390/cancers15041200.


Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study.

Li T, Huang W, Wu Z, Wang Y, Wang Q, Wang Z Curr Oncol. 2022; 29(6):3950-3961.

PMID: 35735425 PMC: 9221598. DOI: 10.3390/curroncol29060316.


Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.

Hatzidakis A, Muller L, Krokidis M, Kloeckner R Cancers (Basel). 2022; 14(10).

PMID: 35626073 PMC: 9139740. DOI: 10.3390/cancers14102469.


Detection of Incomplete Irreversible Electroporation (IRE) and Microwave Ablation (MWA) of Hepatocellular Carcinoma (HCC) Using Iodine Quantification in Dual Energy Computed Tomography (DECT).

Baumler W, Philipp Beyer L, Lurken L, Wiggermann P, Stroszczynski C, Dollinger M Diagnostics (Basel). 2022; 12(4).

PMID: 35454034 PMC: 9026630. DOI: 10.3390/diagnostics12040986.